Compugen Revenue
Biotechnology Research • 
Tel Aviv, Tel-Aviv District, Israel • 101-200 Employees
Compugen revenue & valuation
| Annual revenue | $27,600,000 |
| Revenue per employee | $245,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $88,300,000 |
| Total funding | $20,000,000 |
Key Contacts at Compugen
Liora Bosch
Director, Biostatistics And Programming
Ilana Frishman
Senior Director Of Drug Safety & Pharmacovigilance
Roy Granit
Director, Head Of Computational Discovery At Compugen
Stephen Spence
National Director, Service Portfolio Management
Dan Blat
Director
Amanda Harp
Associate Director Of Clinical Operations, Global Trial Manager
Ran Salomon
Associate Director, Antibody Engineering
Yu Liang
Director, Clinical Biomarker
Ayelet Cooper
Associate Director, Cmc
Carmela Cannarella
Solutions Director
Company overview
| Headquarters | Tel Aviv, Tel-Aviv District, Israel |
| Phone number | +97237658585 |
| Website | |
| NAICS | 541714 |
| SIC | 283 |
| Keywords | Clinical Development, Artificial Intelligence, Machine Learning, Computational Biology, Drug Target Discovery, Immuno-Oncology |
| Employees | 101-200 |
| Socials |
Compugen Email Formats
Compugen uses 5 email formats. The most common is {first name}{last name} (e.g., johndoe@cgen.com), used 65.2% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@cgen.com | 65.2% |
{first initial}{last name} | jdoe@cgen.com | 24.2% |
{first name}.{last name} | john.doe@cgen.com | 6.1% |
{first name} | john@cgen.com | 3% |
{first initial}.{last name} | j.doe@cgen.com | 1.5% |
About Compugen
Compugen is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive AI/ML powered computational discovery platform (Unigen™) to identify new drug targets and biological pathways for developing cancer immunotherapies. Compugen has two proprietary product candidates in Phase 1 development: COM701, a potential first-in-class anti-PVRIG antibody and COM902, a potential best-in-class antibody targeting TIGIT for the treatment of solid tumors. Rilvegostomig, a PD-1/TIGIT bispecific antibody where the TIGIT component is derived from Compugen’s clinical stage anti-TIGIT antibody, COM902, is in Phase 3 development by AstraZeneca through a license agreement for the development of bispecific and multispecific antibodies. GS-0321 (previously COM503), a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is in Phase 1 development is licensed to Gilead. In addition, the Company’s therapeutic pipeline of early-stage immuno-oncology programs consists of research programs aiming to address new mechanisms to activate the immune system against cancer. Compugen is headquartered in Israel, with offices in San Francisco, CA. Compugen’s shares are listed on Nasdaq and the Tel Aviv Stock Exchange under the ticker symbol CGEN.
Employees by Management Level
Total employees: 101-200
Seniority
Employees
Employees by Department
Compugen has 63 employees across 14 departments.
Departments
Number of employees
Compugen Tech Stack
Discover the technologies and tools that power Compugen's digital infrastructure, from frameworks to analytics platforms.
Security
WordPress themes
JavaScript libraries
Page builders
JavaScript libraries
CDN
JavaScript libraries
Programming languages
Security
Blogs
Analytics
Germany
United Kingdom
Frequently asked questions
4.8
40,000 users
